AU750029B2

AU750029B2 - Method of promoting neuronal cell proliferation and diffrentiation

Info

Publication number: AU750029B2
Application number: AU27791/99A
Authority: AU
Inventors: Gere Dizerega; Kathleen E Rodgers
Original assignee: University of Southern California USC
Current assignee: University of Southern California USC
Priority date: 1998-02-19
Filing date: 1999-02-19
Publication date: 2002-07-11
Anticipated expiration: 2019-02-19
Also published as: CA2321164A1; EP1054684A1; WO1999042123A1; JP2002503702A; AU2779199A

Description

WO 99/42123 PCT/US99/03772 METHOD OF PROMOTING NEURONAL CELL PROLIFERATION AND

DIFFERENTIATION

Cross Reference This application is a continuation in part of U.S. Application Serial No. 60/075,232 filed February 19, 1998.

Field of the Invention This present invention relates to methods and kits for accelerating the proliferation and/or differentiation of neuronal cells.

Background of the Invention Stem cells in the central nervous system (hereinafter referred to as "CNS") have the potential to differentiate into neurons, astrocytes, and oligodendrocytes and to self renew.

(McKay, Science 276:66-71, 1997; hereby incorporated by reference in its entirety). CNS progenitor cells have a more restricted potential than a stem cell, while CNS precursor cells comprise any non-fully differentiated CNS cell type (McKay, 1997).

Mammalian fetal precursor cells that give rise to neurons and glia have been isolated (Frederiksen et al., Neuron 1:439 (1988); Reynolds and Weiss, Science 255:1707 (1992); Davis and Temple, Nature 372:263 (1994)). The adult CNS also contains multipotential precursor cells for neurons, astrocytes and oligodendrocytes (McKay, 1997). Cultured cells from both the fetal and adult CNS that have proliferated in vitro can differentiate to show morphological and electrophysiological features characteristic of neurons (Gritti et al., J.

SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Neurosci. 16:1091 (1996); Vicario-Abejon et al., Neuron 15:105 (1995)). These data show the multipotential nature of cells derived from the CNS.

Multipotential cells from the fetal brain have been demonstrated to be both homogenous and stable. (Johe et al., Genes Dev. 10:3129 (1996)). In vitro, these cells divide daily and efficiently generate neurons and glia for at least the first month of culture. These cells can be considered to be stem cells because they fulfill the criteria of multipotency and self-renewal.

Cells from the adult brain proliferate and differentiate into neurons and glia in tissue culture with the same efficiency for neuronal differentiation as found in fetal stem cells and the same response to extracellular ligands (McKay, 1997). Thus, similar general mechanisms control the differentiation of stem cells from fetal or adult brain. The proliferation of precursor cells in the adult forebrain can be stimulated by the direct application of mitogenic growth factors in vivo, and in animals treated in this way, proliferating cells in the subventricular zone differentiate into neurons and glia (Craig et al., J. Neurosci. 16:2649 (1996)). However, in vivo less than 3% of the proliferating cells labeled with bromodeoxyuridine differentiate into neurons (McKay, 1997). The discrepancy between the efficient neuronal differentiation of adult stem cells in vitro and their inefficient differentiation in vivo is a critical but unresolved question in the field The lack of differentiating neurons may not be a consequence of the lack of cells with the appropriate potential but rather a function of the signaling environment in the adult brain (Id.) The long term delivery of proteins in the brain is a major goal in gene therapy.

Transplantation of cells engineered to produce growth factors shows the potential of grafted cells as vectors for protein delivery (Beck et al., Nature 373:339 (1995); Tomac et al., Nature 373:335 (1995); Moore et al., Nature 382:76 (1996)). It is possible to generate many different 2 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 immortal cell lines from the developing CNS. It is also possible to graft primary cells expanded in vitro. Experiments have suggested that primary adult cells derived from the hippocampus and cultured for long periods in vitro can still differentiate into neurons when re-implanted into the migratory pathway used to replenish neurons in the adult olfactory bulb (Suhonen et al., Nature 383:624 (1996)). Experimental grafts in animal models suggest that the integration of grafted neurons into the circuitry of the host may be possible, as other studies illustrate the use of in vitro manipulated donor cells that differentiate in vivo into oligodendrocytes (Tontsch et al., Proc. Natl. Acad. Sci. 91:11616 (1994); Groves et al., Nature 362:453 (1993)). Furthermore, clinical trials show that neuron replacement therapies for neurodegenerative diseases, such as Parkinson's and Huntington's disease, are feasible (Kordower et al., New Engl. J. Med. 332:1118 (1995); Lindvall et al., Ann. Neurol. 35:172 (1994)). Thus, for clinical applications, cell culture offers an important opportunity to use sophisticated genetics in cell-based therapies for neural disease (McKay, 1997).

CNS stem cells have been expanded in vitro by using epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) (McKay, 1997). In vitro, EGF has also been shown to be a differentiation factor for astrocytes.

While these studies demonstrate the potential for stem cell and neuron replacement therapy, a careful analysis of adult neuronal stem cells has only just begun. Further characterization of the mechanisms that control the multipotentiality, self-renewal and fate restriction of neuronal stem cells is clearly important to develop new therapies for cell regeneration and replacement in the adult nervous system. (Johe et al., 1996.) Methods that increase the in vitro and ex vivo proliferation and differentiation of neuronal stem and progenitor cells will greatly increase the utility of neuron replacement therapy in various neurodegenerative conditions such as Parkinson's and Alzheimer's 3 SUBSTITUTE SHEET (RULE 26) Diseases, and amyotropic lateral sclerosis. Similarly, methods that increase in vivo proliferation and differentiation of neuronal stem and progenitor cells will enhance the utility of neuron replacement therapy by rapidly increasing local concentrations of neuronal stem and progenitor cell at the site of therapy.

Summary of the Invention According to a first embodiment of the present invention there is provided a method for promoting neuronal cell proliferation or differentiation comprising contacting neuronal cells with an amount effective to promote proliferation or differentiation of neuronal cells of at least one active agent comprising a sequence of at least three 0t contiguous amino acids of groups R'-R 8 in the sequence of general formula I R R 2

-R

3

-R

4

-R

5 -R -R -R 8 wherein R' is selected from the group consisting of Asp, Glu, Asn, Acpc(laminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 and Suc; i5 R 2 is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

R

3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, and Tyr;

R

4 is selected from the group consisting of Tyr, Tyr(P0 3 2 Thr, Ser, homoSer, 20 Ala, and azaTyr; R is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R

6 is His, Arg or 6-NH 2 -Phe; R is Pro or Ala; and

R

8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr; 25 wherein the active agent does not include R 4 as a terminal Tyr group; and wherein the compound is not SEQ ID NO: 1.

According to a second embodiment of the present invention there is provided a method for promoting neuronal cell proliferation or differentiation comprising contacting neuronal cells with an amount effective to promote proliferation or differentiation of neuronal cells of at least one active agent comprising a sequence consisting of the general ormula: R1 -ARG-VAL-TYR-R2-HIS-PRO-R3 wherein R1 is selected from the group consisting of H or Asp; RR2 is selected from the group consisting of Ile, Val, Leu, norLeu and Ala; 3 5 R3 is either Phe or H; IR \LIHVV\]2429speci.doc'nic t Q 4a and wherein the compound is not SEQ ID NO: 1.

According to a third embodiment of the present invention there is provided use of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R in the sequence of general formula I R -R 2 -R -R 4 -R -R 6

-R

7

-R

8 wherein R' is selected from the group consisting of Asp, Glu, Asn, Acpc(1aminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 and Suc;

R

2 is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

R

4 is selected from the group consisting of Tyr, Tyr(PO 3 2 Thr, Ser, homoSer, Ala, and azaTyr; i R 5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R

6 is His, Arg or 6-NH 2 -Phe;

R

7 is Pro or Ala; and

R

8 is selected from the group consisting of Phe, Phe(Br), lle and Tyr; wherein the active agent does not include R 4 as a terminal Tyr group; 20 and wherein the compound is not SEQ ID NO: 1 for the manufacture of a medicament to promote neuronal cell proliferation or differentiation.

According to a fourth embodiment of the present invention there is provided use of at least one active agent comprising a sequence consisting of the general formula: 2 R1-ARG-VAL-TYR-R2-HIS-PRO-R3 wherein R1 is selected from the group consisting of H or Asp; R2 is selected from the group consisting of Ile, Val, Leu, norLeu and Ala; R3 is either Phe or H; and wherein the compound is not SEQ ID NO:1 for the manufacture of a medicament to promote neuronal cell proliferation or differentiation.

According to a fifth embodiment of the present invention there is provided at least one active agent comprising a sequence of at least three contiguous amino acids of groups I-R in the sequence of general formula I 4 R 'R 2

-R

3

-R

4

-R

5

-R-R

7

R

8 [R:\LIBVV10242 9 speci.doc:nic 4b wherein R' is selected from the group consisting of Asp, Glu, Asn, Acpc(1aminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 and Suc;

R

4 is selected from the group consisting of Tyr, Tyr(P0 3 2 Thr, Ser, homoSer, Ala, and azaTyr; Ic R 5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R

6 is His, Arg or 6-NH 2 -Phe;

R

7 is Pro or Ala; and

R

8 is selected from the group consisting of Phe, Phe(Br), lie and Tyr; o*lo* wherein the active agent does not include R 4 as a terminal Tyr group; i5 and wherein the compound is not SEQ ID NO: 1, when used to promote neuronal cell proliferation or differentiation.

According to a sixth embodiment of the present invention there is provided at least one active agent comprising a sequence consisting of the general formula: R -ARG-VAL-TYR-R2-HIS-PRO-R3 20 wherein RI is selected from the group consisting of H or Asp; R2 is selected from the group consisting of Ile, Val, Leu, norLeu and Ala; R3 is either Phe or H; and wherein the compound is not SEQ ID NO:1, when used to promote neuronal cell prliferation or differentiation.

25 The present invention provides methods that increase the proliferation or differentiation of neuronal stem and progenitor cells that are useful in rapidly providing a large population of such cells for use in neuron replacement therapy and for making a large population of transfected cells for use in neuron replacement therapy.

In one aspect, the present specification describes methods that promote neuronal cell proliferation or differentiation by contacting the cells with angiotensinogen, angiotensin I AI analogues, AI fragments and analogues thereof, angiotensin II (All), All analogues, All fragments and analogues thereof or All AT 2 type 2 receptor AL agonists, either alone or in combination with other growth factors and cytokines.

[R \LIB\'VV]02429speci doc:ijc

,D

4c In another aspect, the present specification describes an improved cell culture medium for the proliferation or differentiation of neuronal cells, wherein the improvement comprises addition to the cell culture medium of an effective amount of angiotensinogen, AI, Al analogues, AI fragments and analogues thereof, All, AII Sanalogues, All fragments or analogues thereof or All AT 2 type 2 receptor agonists.

In a further aspect, the present specification describes kits for the propagation or differentiation of neuronal cells, wherein the kits comprise an effective amount of angiotensinogen, AI, Al analogues, and/or AI fragments and analogues thereof, All, All analogues, All fragments or analogues thereof, and/or All AT 2 type 2 receptor agonists, i and e S *o I R:\L.l3VV02420spcicdoc:ljic WO 99/42123 PCT/US99/03772 instructions for culturing the cells. Preferred embodiments of the kit further comprise cell culture growth medium, a sterile container, and an antibiotic supplement.

Brief Description of the Figures Figure 1. Effect of AII on human neuronal progenitor neurite outgrowth.

Figure 2. Effect of AII, AII(1-7), and Ala4-AIII on the proliferation of normal human neural progenitors.

Detailed Description of the Preferred Embodiments As defined herein, the term "neuronal cells" include either primary cells or established cell lines with the potential to differentiate into neurons, astrocytes, and oligodendrocytes and to self renew, and also to differentiated cells derived therefrom, including fully differentiated CNS and peripheral nervous system cell types. Examples of neuronal stem and progenitor cells include, but are not limited to, those described in Gritti et al., J. of Neuroscience 16:1091-1100 (1996); Frederiksen et al., (1988); Reynolds and Weiss, (1992); Davis and Temple, (1994); McKay, (1997);. Vicario-Abejon et al., (1995); Craig et al., (1996); Tontsch et al. (1994); Graves et al., (1993) and Johe et al., Genes and Develop.

10:3129-3142 (1996), all references hereby incorporated in their entirety. As defined herein, "proliferation" encompasses both cellular self renewal and cellular proliferation with accompanying differentiation.

Unless otherwise indicated, the term "active agents" as used herein refers to the group of compounds comprising angiotensinogen, angiotensin I Al analogues, Al fragments and analogues thereof, angiotensin II (All), AII analogues, All fragments or analogues thereof and AII AT 2 type 2 receptor agonists.

SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression. Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991, Academic Press, San Diego, CA), "Guide to Protein Purification" in Methods in Enzymology Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, CA), Culture of Animal Cells: A Manual of Basic Technique, 2 nd Ed. Freshney. 1987. Liss, Inc. New York, NY), Gene Transfer and Expression Protocols, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, and the Ambion 1998 Catalog (Ambion, Austin, TX).

U.S. Patent No. 5,015,629 to DiZerega (the entire disclosure of which is hereby incorporated by reference) describes a method for increasing the rate of healing of wound tissue, comprising the application to such tissue of angiotensin II (AII) in an amount which is sufficient for said increase. The application of AII to wound tissue significantly increases the rate of wound healing, leading to a more rapid re-epithelialization and tissue repair. The term AII refers to an octapeptide present in humans and other species having the sequence Asp- Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:1]. The biological formation of angiotensin is initiated by the action of renin on the plasma substrate angiotensinogen. The substance so formed is a decapeptide called angiotensin I (AI) which is converted to AII by the converting enzyme angiotensinase which removes the C-terminal His-Leu residues from AI (Asp-Arg- Val-Tyr-Ile-His-Pro-Phe-His-Leu [SEQ ID NO:37]). AII is a known pressor agent and is commercially available. The use of AII analogues and fragments, AT2 agonists, as well as AIII and AIII analogues and fragments in wound healing has also been described. (U.S.

6 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Patent No. 5,629,292; U.S. Patent No. 5,716,935; WO 96/39164; all references herein incorporated by reference in their entirety.) Studies have shown that All increases mitogenesis and chemotaxis in cultured cells that are involved in wound repair, and also increases their release of growth factors and extracellular matrices (diZerega, U.S. Patent No. 5,015,629; Dzau et. al., J. Mol. Cell.

Cardiol. 21:S7 (Supp III) 1989; Berk et. al., Hypertension 13:305-14 (1989); Kawahara, et al., BBRC 150:52-9 (1988); Naftilan, et al., J. Clin. Invest. 83:1419-23 (1989); Taubman et al., J.

Biol. Chem 264:526-530 (1989); Nakahara, et al., BBRC 184:811-8 (1992); Stouffer and Owens, Circ. Res. 70:820 (1992); Wolf, et al., Am. J. Pathol. 140:95-107 (1992); Bell and Madri, Am. J Pathol. 137:7-12 (1990). In addition, All was shown to be angiogenic in rabbit corneal eye and chick chorioallantoic membrane models (Fernandez, et al., J. Lab. Clin. Med.

105:141 (1985); LeNoble, et al., Eur. J. Pharmacol. 195:305-6 (1991). Therefore, AII may accelerate wound repair through increased neovascularization, growth factor release, reepithelialization and/or production of extracellular matrix.

All has also been implicated in both cell growth and differentiation (Meffert et al., Mol. and Cellul. Endocrin. 122:59 (1996)). Two main classes of AII receptors, AT, and AT 2 have been identified (Meffert, 1996). The growth-promoting effects of All have been attributed to mediation by the AT1 receptor, while some evidence suggests that the AT2 receptor may be involved in mediation of the cell differentiation effects of All (Bedecs et al., Biochem. J. 325:449 (1997)).

The effects of All receptor and All receptor antagonists have been examined in two experimental models of vascular injury and repair which suggest that both AII receptor subtypes (AT1 and AT2) play a role in wound healing (Janiak et al., Hypertension 20:737-45 (1992); Prescott, et al., Am. J. Pathol. 139:1291-1296 (1991); Kauffman, et al., Life Sci.

7 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 49:223-228 (1991); Viswanathan, et al., Peptides 13:783-786 (1992); Kimura, et al., BBRC 187:1083-1090 (1992).

Many studies have focused upon AII(1-7) (All residues 1-7) or other fragments of AII to evaluate their activity. AII(1-7) elicits some, but not the full range of effects elicited by All.

Pfeilschifter, et al., Eur. J. Pharmacol. 225:57-62 (1992); Jaiswal, et al., Hypertension 19(Supp. II):II-49-II-55 (1992); Edwards and Stack, J. Pharmacol. Exper. Ther. 266:506-510 (1993); Jaiswal, et al., J. Pharmacol. Exper. Ther. 265:664-673 (1991); Jaiswal, et al., Hypertension 17:1115-1120 (1991); Portsi, et Br. J Pharmacol. 111:652-654 (1994).

Studies have shown that AII inhibits proliferation of both an immortalized neuronal cell line (the pheochromocytoma derived PC12W; Meffert, 1996), and of dissociated primary cultures of retrochiamatic hypothalamus from 18-day old rat embryos (Jirikowski et al., Develop. Brain Res. 14:179-183 (1984)). Other studies have shown that the proportion of AT, and AT 2 receptors in rat brain changes during development, with fetal tissue expressing far more AT 2 receptor subtype, while adult animals express far more AT, subtype (Meffert, 1996). However, little is known about All effects on most CNS or peripheral nervous system cell types. Furthermore, it is not known what All receptor subtypes are expressed by neuronal stem and progenitor cells, nor what effect AII has on their proliferative capacity.

A peptide agonist selective for the AT2 receptor (AII has 100 times higher affinity for AT2 than ATI) is p-aminophenylalanine6-AII ["(p-NH 2 -Phe)6-AII)"], Asp-Arg-Val-Tyr-Ile- Xaa-Pro-Phe [SEQ ID NO.36] wherein Xaa is p-NH 2 -Phe (Speth and Kim, BBRC 169:997- 1006 (1990). This peptide gave binding characteristics comparable to AT2 antagonists in the experimental models tested (Catalioto, et al., Eur. J. Pharmacol. 256:93-97 (1994); Bryson, et al., Eur. J. Pharmacol. 225:119-127 (1992).

8 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 The active AI, AI analogues, AI fragments and analogues thereof, AII analogues, fragments of All and analogues thereof of particular interest in accordance with the present invention are characterized as comprising a sequence consisting of at least three contiguous amino acids of groups RI-R8 in the sequence of general formula I

R'-R

2

-R

3

-R

4

-R

5

-R

6

-R

7

-R

8 in which R' and R 2 together form a group of formula

X-RA-RB,

wherein X is H or a one to three peptide group,

R

A is suitably selected from Asp, Glu. Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 and Sue,

R

8 is suitably selected from Arg, Lys, Ala, Or, Ser(Ac), Sar, D-Arg and D- Lys;

R

3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

R

4 is selected from the group consisting of Tyr, Tyr(PO 3 2 Thr, Ser, homoSer, Ala, and azaTyr;

R

5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R

6 is His, Arg or 6-NH 2 -Phe;

R

7 is Pro or Ala; and

R

8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including R 4 as a terminal Tyr group.

Compounds falling within the category of AT2 agonists useful in the practice of the invention include the AII analogues set forth above subject to the restriction that R 6 is p-NH2- 9 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Phe. In addition to peptide agents, various nonpeptidic agents peptidomimetics) having the requisite AT2 agonist activity are further contemplated for use in accordance with the present invention.

Particularly preferred combinations for RA and RB are Asp-Arg, Asp-Lys, Glu-Arg and Glu-Lys. Particularly preferred embodiments of this class include the following: AII, AIII or AII(2-8), Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:2]; AII(3-8), also known as desl- AIII or AIV, Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:3]; AII(1-7), Asp-Arg-Val-Tyr-Ile-His- Pro {SEQ ID NO:4]; AII(2-7). Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:5]; AII(3-7), Val-Tyr- Ile-His-Pro [SEQ ID NO:6]; AII(5-8), Ile-His-Pro-Phe [SEQ ID NO:7]; AII(1-6), Asp-Arg- Val-Tyr-Ile-His [SEQ ID NO:8]; AII(1-5), Asp-Arg-Val-Tyr-Ile [SEQ ID NO:9]; AII(1-4), Asp-Arg-Val-Tyr [SEQ ID NO:10]; and AII(1-3), Asp-Arg-Val [SEQ ID NO:11]. Other preferred embodiments include: Arg-norLeu-Tyr-Ile-His-Pro-Phe [SEQ ID NO:12] and Arg- Val-Tyr-norLeu-His-Pro-Phe [SEQ ID NO:13]. Still another preferred embodiment encompassed within the scope of the invention is a peptide having the sequence Asp-Arg-Pro- Tyr-Ile-His-Pro-Phe [SEQ ID NO:31]. AII(6-8), His-Pro-Phe [SEQ ID NO:14] and AII(4-8), Tyr-Ile-His-Pro-Phe [SEQ ID NO: 15] were also tested and found not to be effective.

In another preferred embodiment, the present invention provides a method for promoting neuronal cell proliferation or differentiation comprising contacting neuronal cells with an amount effective to promote proliferation or differentiation of at least one active agent comprising a sequence consisting of the general formula: R1-ARG-VAL-TYR-R2-HIS-PRO-R3 wherein RI is selected from the group consisting of H or Asp; R2 is selected from the group consisting of Ile, Val, Leu, norLeu and Ala; R3 is either Phe or H.

SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 In a most preferred embodiment, the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:26, and SEQ ID NO:34.

Another class of compounds of particular interest in accordance with the present invention are those of the general formula II R2-R3 R -RS-R'-R-R 8 in which R 2 is selected from the group consisting of H, Arg, Lys, Ala, Om, Ser(Ac), Sar, D-Arg and D-Lys;

R

3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R

4 is selected from the group consisting of Tyr, Tyr(PO 3 2 Thr, Ser, homoSer and azaTyr;

R

5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R

6 is His, Arg or 6-NH 2 -Phe;

R

7 is Pro or Ala; and R is selected from the group consisting of Phe, Phe(Br), Ile and Tyr.

A particularly preferred subclass of the compounds of general formula II has the formula

R

2 -R-Tyr-RS-His-Pro-Phe [SEQ ID NO:16] wherein R 2

R

3 and R 5 are as previously defined. Particularly preferred is angiotensin III of the formula Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:2]. Other preferred compounds include peptides having the structures Arg-Val-Tyr-Gly-His-Pro-Phe [SEQ ID NO:17] and 11 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/S99/03772 Arg-Val-Tyr-Ala-His-Pro-Phe [SEQ ID NO:18]. The fragment AII(4-8) was ineffective in repeated tests; this is believed to be due to the exposed tyrosine on the N-terminus.

In the above formulas, the standard three-letter abbreviations for amino acid residues are employed. In the absence of an indication to the contrary, the L-form of the amino acid is intended. Other residues are abbreviated as follows: TABLE 1 Abbreviation for Amino Acids Me 2 Glv N,N-dimethylglycyl Bet 1-carboxy-N,N,N-trimethylmethanaminium hydroxide inner salt (betaine) Suc Succinyl Phe(Br) p-bromo-L-phenvllalnyl azaTyr aza-a '-homo-L-tyrosyl Acpc 1-aminocyclopentane carboxylic acid Aib 2-aminoisobutvric acid Sar N-methylglycyl (sarcosine) It has been suggested that AII and its analogues adopt either a gamma or a beta turn (Regoli, et al., Pharmacological Reviews 26:69 (1974). In general, it is believed that neutral side chains in position R 3

R

5 and R 7 may be involved in maintaining the appropriate distance between active groups in positions R 4

R

6 and R 8 primarily responsible for binding to receptors and/or intrinsic activity. Hydrophobic side chains in positions R 3

R

5 and R 8 may also play an important role in the whole conformation of the peptide and/or contribute to the formation of a hypothetical hydrophobic pocket.

12 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Appropriate side chains on the amino acid in position R 2 may contribute to affinity of the compounds for target receptors and/or play an important role in the conformation of the peptide. For this reason, Arg and Lys are particularly preferred as R 2 For purposes of the present invention, it is believed that R 3 may be involved in the formation of linear or nonlinear hydrogen bonds with R' (in the gamma turn model) or R 6 (in the beta turn model). R 3 would also participate in the first turn in a beta antiparallel structure (which has also been proposed as a possible structure). In contrast to other positions in general formula I, it appears that beta and gamma branching are equally effective in this position. Moreover, a single hydrogen bond may be sufficient to maintain a relatively stable conformation. Accordingly, R 3 may suitably be selected from Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr. In another preferred embodiment, R 3 is Lys.

With respect to R 4 conformational analyses have suggested that the side chain in this position (as well as in R 3 and R 5 contribute to a hydrophobic cluster believed to be essential for occupation and stimulation of receptors. Thus, R 4 is preferably selected from Tyr, Thr, Tyr (P0 3 2 homoSer, Ser and azaTyr. In this position, Tyr is particularly preferred as it may form a hydrogen bond with the receptor site capable of accepting a hydrogen from the phenolic hydroxyl (Regoli, et al. (1974), supra). In a further preferred embodiment, R 4 is Ala.

In position R 5 an amino acid with a P aliphatic or alicyclic chain is particularly desirable. Therefore, while Gly is suitable in position R 5 it is preferred that the amino acid in this position be selected from Ile, Ala, Leu, norLeu, Gly and Val.

In the AI, AI analogues, AI fragments and analogues thereof, AII, AII analogues, fragments and analogues of fragments of particular interest in accordance with the present invention, R 6 is His, Arg or 6-NH 2 -Phe. The unique properties of the imidazole ring of histidine ionization at physiological pH, ability to act as proton donor or acceptor, 13 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 aromatic character) are believed to contribute to its particular utility as R 6 For example, conformational models suggest that His may participate in hydrogen bond formation (in the beta model) or in the second turn of the antiparallel structure by influencing the orientation of

R

7 Similarly, it is presently considered that R 7 should be Pro in order to provide the most desirable orientation of R 8 In position R 8 both a hydrophobic ring and an anionic carboxyl terminal appear to be particularly useful in binding of the analogues of interest to receptors; therefore, Tyr and especially Phe are preferred for purposes of the present invention.

Analogues of particular interest include the following: TABLE 2 Angiotensin II Analogues AII Analogue Amino Acid Sequence Sequence Name Identifier Analogue 1 Asp-Arg-Val-Tyr-Val-His-Pro-Phe SEQ ID NO: 19 Analogue 2 Asn-Arg-Val-Tyr-Val-His-Pro-Phe SEQ ID NO: Analogue 3 Ala-Pro-Gly-Asp-Arg-Ile-Tyr-Val-His-Pro-Phe SEQ ID NO: 21 Analogue 4 Glu-Arg-Val-Tyr-Ile-His-Pro-Phe SEQ ID NO: 22 Analogue 5 Asp-Lys-Val-Tyr-Ile-His-Pro-Phe SEQ ID NO: 23 Analogue 6 Asp-Arg-Ala-Tyr-Ile-His-Pro-Phe SEQ ID NO: 24 Analogue 7 Asp-Arg-Val-Thr-Ile-His-Pro-Phe SEQ ID NO: Analogue 8 Asp-Arg-Val-Tyr-Leu-His-Pro-Phe SEQ ID NO: 26 Analogue 9 Asp-Arg-Val-Tyr-Ile-Arg-Pro-Phe SEQ ID NO: 27 Analogue 10 Asp-Arg-Val-Tyr-Ile-His-Ala-Phe SEQ ID NO: 28 Analogue 11 Asp-Arg-Val-Tyr-Ile-His-Pro-Tyr SEQ ID NO: 29 Analogue 12 Pro-Arg-Val-Tyr-Ile-His-Pro-Phe SEQ ID NO: Analogue 13 Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe SEQ ID NO: 31 Analogue 14 Asp-Arg-Val-Tyr(P0 3 2 -Ile-His-Pro-Phe SEQ ID NO: 32 Analogue 15 Asp-Arg-norLeu-Tyr-Ile-His-Pro-Phe SEQ ID NO: 33 Analogue 16 Asp-Arg-Val-Tyr-norLeu-His-Pro-Phe SEQ ID NO: 34 Analogue 17 Asp-Arg-Val-homoSer-Tyr-Ile-His-Pro-Phe SEQ ID NO: The polypeptides of the instant invention may be synthesized by methods such as those set forth in J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co., Rockford, Ill. (1984) and J. Meienhofer, Hormonal Proteins and 14 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Peptides. Vol. 2, Academic Press, New York, (1973) for solid phase synthesis and E.

Schroder and K. Lubke, The Peptides, Vol. 1, Academic Press, New York, (1965) for solution synthesis. The disclosures of the foregoing treatises are incorporated by reference herein.

In general, these methods involve the sequential addition of protected amino acids to a growing peptide chain Patent No. 5,693,616, herein incorporated by reference in its entirety). Normally, either the amino or carboxyl group of the first amino acid and any reactive side chain group are protected. This protected amino acid is then either attached to an inert solid support, or utilized in solution, and the next amino acid in the sequence, also suitably protected, is added under conditions amenable to formation of the amide linkage.

After all the desired amino acids have been linked in the proper sequence, protecting groups and any solid support are removed to afford the crude polypeptide. The polypeptide is desalted and purified, preferably chromatographically, to yield the final product.

In one aspect of the present invention, a method of increasing in vivo, in vitro and ex vivo neuronal stem and progenitor cell proliferation by exposure to angiotensinogen, AI, AI analogues, AI fragments and analogues thereof, AII analogues, AII fragments or analogues thereof or AII AT 2 type 2 receptor agonists ("active agents") is disclosed. Experimental conditions for the isolation, purification, in vitro/ex vivo growth and in vivo mobilization of neuronal stem and progenitor cells have been reported (Frederiksen et al., 1988; Reynolds and Weiss, 1992; Gritti et al., 1996; Vicario-Abejon et al., 1995; Johe et al., 1996; Craig et al., 1996; Suhonen et al., Nature 383:624-627, 1996; and Tontsch et al., 1994).

Proliferation can be quantitated using any one of a variety of techniques well known in the art, including, but not limited to, bromodeoxyuridine incorporation (Vicario-Abejon et al., 1995), 3 H-thymidine incorporation (Fredericksen et al., 1988), or antibody labeling of a protein present in higher concentration in proliferating cells than in non-proliferating cells. In SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 a preferred embodiment, proliferation of neuronal stem and progenitor cells is assessed by reactivity to an antibody directed against a protein known to be present in higher concentrations in proliferating cells than in non-proliferating cells, including but not limited to proliferating cell nuclear antigen (PCNA, or cyclin; Zymed Laboratories, South San Francisco, California).

In one embodiment, neuronal cells are isolated from primary cell masses according to standard methods (Jirikowski et al., 1984; Reynolds and Weiss, 1992; Johe et al., 1996; Gritti et al., 1996; Vicario-Abejon et al., 1995; Kordower et al., 1995; Nauert and Freeman, Cell Transplant 3:147-151, 1994; Freeman and Kordower, In: Lindvall et al., eds. Intracerebral Transplantation in Movement Disorders. New York: Elsevier Science, 163-170, 1991), suspended in culture medium and incubated in the presence of, preferably, between about 0.1 ng/ml and about 10 mg/ml of the active agents of the invention. The cells are expanded for a period of between 8 and 21 days and cellular proliferation is assessed as described above.

In a preferred embodiment, neuronal stem and progenitor cells are isolated from primary cells which are isolated from the adult rat mammalian forebrain or rat embryonic hippocampus (Johe et al., 1996). The cell mass is dissociated by either mechanical trituration or by incubating minced tissue in Hank's Buffered Saline Solution (HBSS). The cells are collected by centrifugation and resuspended in a serum-free medium containing Dulbecco's modified Eagle medium (DMEM)/F12, glucose, glutamine, sodium bicarbonate, 25 pg/ml of insulin, 100 ug/ml of human apotransferrin, 20 nm progesterone, 100 gim putrescene, 30 nm sodium selenite (pH plus 10 ng/ml of recombinant basic fibroblast growth factor (bFGF; R&D, Inc.) (Johe et al., 1996). The cells are plated into tissue culture plates precoated with cell attachment factors, as is well known in the art. BFGF is added daily, and the medium is 16 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 changed every two days. Cells are passaged at 50% confluence by briefly incubating them in HBSS and scraping with a cell scraper.

Alternatively, neuronal stem and progenitor cells are isolated from the dissociated cell mass by antibody-mediated cell capture ("panning"; Barres et al., Cell 70:31-46, 1992).

Antibodies that can be used to isolate neuronal stem and precursor cells include, but are not limited to, nestin antibody (Vicario-Abejon et al., 1995). The cells are then treated as above.

The neuronal stem and progenitor cells exposed to the active agents as described above can be used for neuron replacement therapy, to treat disorders including, but not limited to, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis. The cells are cultured in vitro or ex vivo as described above. The cells are rinsed to remove all traces of culture fluid, resuspended in an appropriate medium and then pelleted and rinsed several times. After the final rinse, the cells are resuspended at between 0.7 x 10 6 and 50 x 106 cells per ml in an appropriate medium and used for transplantation according to previously described methods. (Kordower et al., 1995; Freed et al., N. Engl. J. Med. 327:1549-1555, 1992; Ann. Neurol. 31:155-165, 1992; Peschanski et al., Brain 117:487-499, 1994; Spencer et al., N. Engl. J. Med. 327:1541-1548, 1992; Henderson et al., Arch. Neurol. 48:822-827, 1992; Hitchcock et al., Exp. Neurol. 129:3, 1994; Lindvall et al., Science 247:574-577, 1990; Widner et al., N. Engl. J. Med. 327:1556-1563, 1992; Bankiewicz et al., J. Neurosurg.

72:231-244, 1990; Kordower et al., Ann. Neurol. 29:405-412, 1991) In a preferred embodiment, the neuronal stem and progenitor cells used for transplantation are transfected with an expression vector so as to express a therapeutic protein, including but not limited to glial-cell-line-derived neurotrophic factor (GDNF; Beck et al.

Nature 373:339-341, 1995; Tomac et al., Nature 373:335-339, 1995) after transplantation.

17 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 In a further aspect of the present invention, the effect of the active agents on neuronal stem and progenitor cell differentiation is assessed by examination of changes in gene expression, phenotype, morphology, or any other method that distinguishes stem and/or progenitor cells from fully differentiated cells. Examples of such differentiation markers against which antibodies are available include, but are not limited to, neuron-specific microtubule-associated protein 2 (MAP2; Vicario-Abejon et al., 1995; antibody available from Boehringer Manheim, Germany), astroglial-specific glial fibrillary acidic protein (GFAP; Vicario-Abejon et al., 1995; antibody available from Incstar,); neuron-specific tau protein (Johe et al., 1996; antibody available from Sigma, St. Louis, MO); neurofilaments L and M (Johe et al., 1996; antibody available from Boehringer Manheim); and oligodendrocyte-specific 04 and galactocerebroside (GalC; Johe et al., 1996). The DNA sequences for all of these differentiation-specific markers are known, and thus PCR amplification and/or hybridization studies to evaluate gene expression of the differentiation markers can be performed according to standard methods in the art. (Johe et al., 1996) In a preferred embodiment, neuronal stem and progenitor cells are isolated and cultured as described above. Differentiation is initiated by contacting the cells with the active agents as described above, in serum-free medium in the absence of bFGF.

Differentiation is assessed at various times by immunodetection of differentiation-specific markers, using the antibodies described above (Johe et al., 1996). Alternatively, differentiation is assessed morphologically by measurement of neurite outgrowth.

In another aspect of the present invention the active agents are used to increase in vivo neuronal stem and progenitor cell proliferation. For use in increasing proliferation of neuronal stem and progenitor cells, the active agents may be administered by any suitable route, including orally, parentally, by inhalation spray, rectally, or topically in dosage unit 18 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intraarterial, intra-ventricular, intramuscular, intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques or intraperitoneally.

The active agents may be made up in a solid form (including granules, powders or suppositories) or in a liquid form solutions, suspensions, or emulsions) and may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

While the active agents can be administered as the sole active agent, they can also be used in combination with one or more other compounds. When administered as a combination, the active agents and other compounds can be formulated as separate compositions that are given at the same time or different times, or the active agents and other compounds can be given as a single composition.

For administration, active agents are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include 19 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.

The dosage regimen for increasing in vivo proliferation or differentiation of neuronal stem and progenitor cell with the active agents of the invention is based on a variety of factors, including the type of injury or deficiency, the age, weight, sex, medical condition of the individual, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely by a physician using standard methods. Dosage levels of the order of between 0.1 ng/kg and 10 mg/kg angiotensinogen, AI, AI analogues, AI fragments and analogues thereof, AII, AII analogues, AII fragments and analogues thereof and/or AII AT 2 type 2 receptor agonists per body weight are useful for all methods of use disclosed herein.

In a preferred embodiment of the present invention, the active agents are administered by unilateral infusion directly into the mammalian brain lateral ventricle using an osmotic pump (Alza Palo Alto, CA) attached to a 30 gauge cannulae implanted at the injection coordinate, as described in Craig et al., J. of Neuroscience 16:2649-2658 (1996). A suitable injected dose of active ingredient of the active agents is preferably between about 0.1 ng/kg and about 10 mg/kg administered twice daily. The active ingredient may comprise from 0.001% to 10% w/w, from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 In another aspect of the present invention, an improved cell culture medium is provided for the proliferation and differentiation of neuronal cells, wherein the improvement comprises addition to the cell culture medium of an effective amount of the active agents, as described above. Any cell culture media that can support the growth of neuronal stem and progenitor cells can be used with the present invention. Such cell culture media include, but are not limited to Basal Media Eagle, Dulbecco's Modified Eagle Medium, Iscove's Modified Dulbecco's Medium, McCoy's Medium, Minimum Essential Medium, F-10 Nutrient Mixtures, Opti-MEM® Reduced-Serum Medium, RPMI Medium, and Macrophage-SFM Medium or combinations thereof.

The improved cell culture medium can be supplied in either a concentrated (ie: or non-concentrated form, and may be supplied as either a liquid, a powder, or a lyophilizate.

The cell culture may be either chemically defined, or may contain a serum supplement.

Culture media is commercially available from many sources, such as GIBCO BRL (Gaithersburg, MD) and Sigma (St. Louis, MO) In a further aspect, the present invention provides kits for the propagation of neuronal stem and progenitor cells, wherein the kits comprise an effective amount of the active agents, as described above.

In a preferred embodiment, the kit further comprises cell culture growth medium. Any cell culture media that can support the growth of neuronal stem and progenitor cells can be used with the present invention. Examples of such cell culture media are described above.

21 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 In another preferred embodiment, the kit further comprises a sterile container. The sterile container can comprise either a sealed container, such as a cell culture flask, a roller bottle, or a centrifuge tube, or a non-sealed container, such as a cell culture plate or microtiter plate (Nunc; Naperville, IL).

In a further preferred embodiment, the kit further comprises an antibiotic supplement for inclusion in the reconstituted cell growth medium. Examples of appropriate antibiotic supplements include, but are not limited to actimonycin D, Fungizone®, kanamycin, neomycin, nystatin, penicillin, streptomycin, or combinations thereof (GIBCO).

The present invention may be better understood with reference to the accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

Example 1. Al Effect on the Proliferation and Differentiation of Normal Human Neuronal Progenitor Cells Normal human progenitor cells were purchased from Clonetics (San Diego, CA) and cultured in Neural Progenitor Cell Maintenance Medium (NPMM) (Neural Progenitor Basal Medium containing human recombinant fibroblast growth factor beta, human recombinant epidermal growth factor, neural survival factors, gentamycin and amphotericin The cells were thawed, diluted into NPMM and cultured for 24 hours in a 75 cm 2 flask. The cells were cultured in dedifferentiaited spheroids until studies were conducted to assess differentiation.

When the cells were cultured in suspension culture in the presence of 1, 10, or 100 tg/ml AII for 4-7 days prior to placement of the cells on a culture substrate that allowed adherence and differentiation (as described further below), an increase in the number of cells able to undergo differentiation (ie: proliferation) was observed (Table I).

22 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Table I. Effect of All on the Proliferation of Human Neuronal Progenitor Cells All Concentration Cells per Well on Day 4 Cells per Well on Da 7 0 Ag/ml 66 63 1 gg/ml 93 g/ml 89 86 100 ugml 91 86 Assessment of Differentiation In order to assess the differentiation of neuronal cells, the cells were seeded upon wells coated with 0.05% polyethyleneimine (PEI) substrate in borate buffer solution. The wells of a 96 well plate were coated with 0.05 ml of this solution overnight at room temperature. After the incubation, the substrate was removed by aspiration, rinsed with sterile water and allowed to dry before seeding of the cells.

After culture of cells for 4-7 days in the presence of All (to assess proliferation), the cells were washed and placed in PEI-coated wells to assess differentiation. Four days after plating, the number of cells undergoing differentiation, as assessed by neurite outgrowth, was counted (see Table 1).

In an additional study, the effect of AII on the differentiation of neuronal progenitor cells was assessed. After adherence to PEI substrate, the cells cease proliferation and undergo differentiation and neurite outgrowth. One thousand cells were placed in each well in the presence and absence of various concentrations of All. Four and seven days after initiation of culture, the size of the neurites (by measurement with an ocular micrometer) on the cells undergoing differentiation and the number of cells undergoing differentiation was assessed.

Culture of the cells in the presence of AII increased the rate of neurite outgrowth (see Figure 1) and the number of cells undergoing differentiation by approximately 50% (data not shown).

23 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 These studies demonstrate that exposure to AII promotes the proliferation and differentiation of normal human neuronal progenitor cells.

Example 2. Effect of All, AII(1-7), and ALa4-AIII on the proliferation of normal human neural progenitors Normal human progenitor cells were purchased from Clonetics (San Diego, CA) and cultured in Neuronal Progenitor Cell Maintenance Medium (NPMM) (Neural Progenitor Basal Medium containing human recombinant fibroblast growth factor beta, human recombinant epidermal growth factor, neural survival factors, gentamycin, and amphotericin The cells were thawed, diluted into NPMM and cultured for 24 hours in a 75 cm 2 flask.

Until studies to assess differentiation, the cells were cultured in dedifferentiated spheroids. If the cells were cultured in suspension culture in the presence of 10 gg/ml AII (SEQ ID NO:1), AII(1-7) (SEQ ID NO:4), or Ala4-AIII (SEQ ID NO:18) for 7 days prior to placement of the cells on collagen-coated plates to allow adherence, an increase in the number of cells able to undergo proliferation was observed (Figure The increase in the number of human neural progenitors in the wells was 300% in the presence of All, 175% in the presence of Ala4-AIII, and 100% in the presence of AII(1-7), while the increase was only 33% in the control wells.

These studies show that each of these peptides promoted the proliferation of normal human neuronal progenitor cells.

The present invention, by providing a method for enhanced proliferation of neuronal cells, will greatly increase the clinical benefits of neuronal stem and progenitor transplantation. This is true both for increased "self-renewal" of neuronal stem cells, which will provide a larger supply of stem cells capable of differentiation into various neuronal cell types, and for proliferation with differentiation, which will provide a larger supply of neuronal progenitor and differentiated cells at the appropriate site. Similarly, methods that increase in 24 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 vivo proliferation of neuronal stem, progenitor, and differentiated cells are beneficial in treating many neurological disorders, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.

The method of the present invention also increases the potential utility of neuronal stem and progenitor cells as vehicles for gene therapy in central and peripheral nervous system disorders by more efficiently providing a large number of such cells for transfection, and also by providing a more efficient means to rapidly expand transfected neuronal stem and progenitor cells.

The present invention is not limited by the aforementioned particular preferred embodiments. It will occur to those ordinarily skilled in the art that various modifications may be made to the disclosed preferred embodiments without diverting from the concept of the invention. All such modifications are intended to be within the scope of the present invention.

SUBSTITUTE SHEET (RULE 26) EDITORIAL NOTE NO. 27791199 The sequence listing is numbered from page 1-23.

The claims pages follow, starting from page number 26.

WO 99/42123PCJS9072 PCT/US99/03772 SEQUENCE LISTING <210> 1 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII <400> 1 Asp Arg Val Tyr Ile His Pro Phe 1 <210> 2 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (2-8) <400> 2 Arg Val Tyr Ile His Pro Phe SUBSTITUTE SHEET (RULE 26) WO 99/42123 PTU9/37 PCTIUS99/03772 1 <210> 3 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (3-8) <400> 3 Val Tyr Ile His Pro Phe 1 <210> 4 <211> 7 <212> PET <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (1-7) 2 SUBSTITUTE SHEET (RULE 26) WO 99/42123 <400> 4 Asp Arg Val Tyr Ile His Pro PCT/US99/03772 <210> <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (2-7) <400> Arg Val Tyr Ile His Pro 1 <210> 6 <2111> <212> PRT <213> Artificial Sequence <220> SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCTIS99/03772 <223> Description of Artificial Sequence:AII (3-7) <400> 6 Val Tyr Ile His Pro <210> 7 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (5-8) <400> 7 Ile His Pro Phe 1 <210> 8 <211> 6 <212> PRT <213> Artificial Sequence SUBSTITUTE SHEET (RULE 26) WO 99/42123 PTU9/37 PCT/US99/03772 <220> <223> Description of Artificial Sequence:AII (1-6) <400> 8 Asp Arg Val Tyr Ile His 1 <210> 9 <211> <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (1-S) <400> 9 Asp Arg Val Tyr Ile 1 <210> <211> 4 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PTU9/37 PCT[US99/03772 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (1-4) <400> Asp Arg Val Tyr 1 <210> 11 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (1-3) <400> 11 Asp Arg Val SUBSTITUTE SHEET (RULE WO 99/42123 PCT/US99/03772 <210> 12 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue <220> <221> MOD RES <222> (2) <223> Nle <400> 12 Arg Xaa Tyr Ile His Pro Phe 1 <210> 13 <211> 7 <212> PRT <213> Artificial Sequence <220> 7 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PTU9/37 PCTIUS99/03772 <223> Description of Artificial Sequence:AII analogue <220> <221> MODRES <222> (4) <223> Nie <400> 13 Arg Val Tyr Xaa His Pro Phe 1 <210> 14 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (6-8) <400> 14 His Pro Phe 1 8 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 <210> <211> <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII (4-8) <400> Tyr Ile His Pro Phe 1 <210> 16 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue class <220> 9 SUBSTITUTE SHEET (RULE 26) WO 99/42123 WO 9942123PCT/US99/03772 <221> UNSURE <222> (1) <223> Xaa at poistion 1 can be Arg, Lys, Ala, Orn, Ser, MeGly, D-Arg, or D-Lys <220> <221> UNSURE <222> (2) <223> Xaa at position 2 can be Val, Ala, Leu, Nie, Ile, Gly, Pro, Aib, Acp, or Tyr <220> <221> UNSURE <222> (4) <223> Xaa at position 4 can be Ile, Ala, Leu, Nie, Val, or Gly <400> 16 Xaa Xaa Tyr Xaa His Pro Phe 1 <210> 17 <211> 7 SUBSTITUTE SHEET (RULE WO 99/42123 PCT/US99/03772 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue <400> 17 Arg Val Tyr Gly His Pro Phe 1 <210> 18 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue <400> 18 Arg Val Tyr Ala His Pro Phe 1 11 SUBSTITUTE SHEET (RULE 26) WO 99/42123 WO 9942123PCTIUS99/03772 <210> <211> <212> <213> 19 8

PRT

Artificial Sequence Description of Artificial Sequence:AII analogue 1 <220> <223> <400> 19 Asp Arg Val Tyr Val His Pro Phe 1 <210> <211> <212> <213> <220> <223> 8

PRT

Artificial Sequence Description of Artificial Sequence:AII analogue 2 <400> Asn Arg Val Tyr Val His Pro Phe 1 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 <210> 21 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 3 <400> 21 Ala Pro Gly Asp Arg Ile Tyr Val His Pro Phe 1 5 <210> 22 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 4 <400> 22 13 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 Glu Arg Val Tyr Ile His Pro Phe 1 <210> 23 <211> 8 <212> PRT <213> Artificial Sequence Description of Artificial Sequence:AII analogue <220> <223> <400> 23 Asp Lys Val Tyr Ile His Pro Phe 1 <210> <211> <212> <213> <220> <223> 24 8

PRT

Artificial Sequence Description of Artificial Sequence:AII analogue 6 14 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 <400> 24 Asp Arg Ala Tyr Ile His Pro Phe 1 <210> <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 7 <400> Asp Arg Val Thr Ile His Pro Phe 1 <210> 26 <211> 8 <212> PRT <213> Artificial Sequence SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 <220> <223> Description of Artificial Sequence:AII analogue 8 <400> 26 Asp Arg Val Tyr Leu His Pro Phe 1 <210> 27 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 9 <400> 27 Asp Arg Val Tyr Ile Arg Pro Phe 1 <210> 28 <211> 8 <212> PRT 16 SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue <400> 28 Asp Arg Val Tyr Ile His Ala Phe <210> 29 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 11 <400> 29 Asp Arg Val Tyr Ile His Pro Tyr <210> SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99/03772 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 12 <400> Pro Arg Val Tyr Ile His Pro Phe 1 <210> 31 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 13 <400> 31 Asp Arg Pro Tyr Ile His Pro Phe 1 18, SUBSTITUTE SHEET (RULE 26) WO 99/42123 PCT/US99103772 <210> 32 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 14 <220> <221> MODRES <222> (4) <223> PHOSPHORYLATION <400> 32 Asp Arg Val Tyr Ile His Pro Phe 1 <210> 33 <211> 8 <212> PRT <213> Artificial Sequence 19 SUBSTITUTE SHEET (RULE WO 99/42123 WO 9942123PCTIUS99/03772 <220> <223> Description of Artificial Sequence:AII analogue <220> <221> MODRES <222> (3) <223> Nie <400> 33 Asp Arg Xaa Tyr Ile His Pro Phe 1 <210> 34 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 16 <220> <221> MODRES <222> SUBSTITUTE SHEET (RULE WO 99/42123 WO 9942123PCT/US99/03772 <223> Nie <400> 34 Asp Arg Val Tyr Xaa His Pro Phe 1 <210> <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence:AII analogue 17 <220> <221> MODRES <222> (4) <223> homo, Ser <400> Asp Arg Val Ser Tyr Ile His Pro Phe 1 21 SUBSTITUTE SHEET (RULE WO 99/42123 PTU9137 PCT/US99/03772 <210> 36 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence :p-aminophenylalanine 6 All <220> <221> MODRES <222> (6) <223> p-aminophenylalanine <400> 36 Asp Arg Val Tyr Ile Xaa Pro Phe 1 <210> 37 <211> <212> PRT <213> Artificial Sequence 22 SUBSTITUTE SHEET (RULE WO 99/42123 WO 9942123PCTIUS99/03772 <220> <223> Description of Artificial Sequence:angioterasin I .<400> 37 Asp Arg Val Tyr Ile His Pro Phe His Leu SUBSTITUTE SHEET (RULE

Claims

1. A method for promoting neuronal cell proliferation or differentiation comprising contacting neuronal cells with an amount effective to promote proliferation or differentiation of neuronal cells of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R'-R in the sequence of general formula I R'-R 2 -R 3 -R 4 -R-R -R 7 -R wherein R1 is selected from the group consisting of Asp, Glu, Asn, Acpc(l- aminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 and Sue; Io R 2 is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R 3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, and Tyr; R 4 is selected from the group consisting of Tyr, Tyr(PO 3 2 Thr, Ser, homoSer, 5 Ala, and azaTyr; R 5 is selected from the group consisting of lie, Ala, Leu, norLeu, Val and Gly; R 6 is His, Arg or 6-NH 2 -Phe; R 7 is Pro or Ala; and R 8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr; 1 20 wherein the active agent does not include R 4 as a terminal Tyr group; and wherein the compound is not SEQ ID NO: 1.

2. The method of claim 1 wherein the active agent is selected from the group consisting of angiotensinogen, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ 25 ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23. SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36; and SEQ ID NO:37.

3. The method of claim 1 or 2 wherein the active agent is SEQ ID NO:4, or SEQ ID NO:18.

4. The method of any one of claims 1 to 3 wherein the concentration of active agent is between about 0.1 ng/kg and about 10.0mg/kg.

5. A method for promoting neuronal cell proliferation or differentiation S s mprising contacting neuronal cells with an amount effective to promote proliferation or [R.\LI It VV]02429speci.doc:nic 27 differentiation of neuronal cells of at least one active agent comprising a sequence consisting of the general formula: RI -ARG-VAL-TYR-R2-HIS-PRO-R3 wherein R1 is selected from the group consisting of H or Asp; R2 is selected from the group consisting of lle, Val, Leu, norLeu and Ala; R3 is either Phe or H; and wherein the compound is not SEQ ID NO: 1.

6. The method of claim 5 wherein the active agent is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO:18, SEQ ID i0 NO: 19, SEQ ID NO:26, and SEQ ID NO:34.

7. The method of claim 5 or 6 wherein the concentration of active agent is between about 0. Ing/kg and about 10.0mg/kg.

8. The method of claim 1 wherein the active agent comprises at least four *contiguous amino acids of general formula I.

9. The method of claim 1 wherein the active agent comprises at least five "contiguous amino acids of general formula I. The method of claim 1 wherein the active agent comprises at least six contiguous amino acids of general formula I.

11. The method of claim 1 wherein the active agent comprises at least seven 20 contiguous amino acids of general formula I.

12. The method of claim 1 wherein the active agent consists of at least three o contiguous amino acids of general formula I.

13. The method of claim 1 wherein the active agent consists of at least four S* contiguous amino acids of general formula I.

14. The method of claim 1 wherein the active agent consists of at least five contiguous amino acids of general formula I. The method of claim 1 wherein the active agent consists of at least six contiguous amino acids of general formula I.

16. The method of claim 1 wherein the active agent consists of at least seven contiguous amino acids of general formula I. I :\IIl\VV 0242)speci.doc ncj II 28

17. A method for promoting neuronal cell proliferation or differentiation comprising contacting neuronal cells with an amount effective to promote proliferation or differentiation of neuronal cells of at least one active agent, which agent is substantially as herein described with reference to Example 1 or 2. S18. Use of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R'-R 8 in the sequence of general formula 1 R'-R 2 -R R 4 -R -R-R 7 R 8 wherein R' is selected from the group consisting of Asp, Glu, Asn, Acpc(l- aminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 io and Suc; R 2 is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R 3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, and Tyr; I R 4 is selected from the group consisting of Tyr, Tyr(PO 3 2 Thr, Ser, homoSer, Ala, and azaTyr; R is selected from the group consisting of lie, Ala, Leu, norLeu, Val and Gly; R 6 is His, Arg or 6-NH 2 -Phe; R 7 is Pro or Ala; and 2o0 R 8 is selected from the group consisting of Phe, Phe(Br), lie and Tyr; wherein the active agent does not include R 4 as a terminal Tyr group; and wherein the compound is not SEQ ID NO: 1 for the manufacture of a medicament to promote neuronal cell proliferation or differentiation. 25 19. The use of claim 18 wherein the active agent is selected from the group consisting of angiotensinogen, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36; and SEQ ID NO:37. The use of claim 18 or 19 wherein the active agent is SEQ ID NO:4, or SEQ ID NO:18. \l.11VV| 242) I l ci.d oc njc E f 0 S 0 S 29

21. The use of any one of claims 18 to 20 wherein the concentration of active agent is between about 0. Ing/kg and about 10.0mg/kg.

22. Use of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R'-R 8 in the sequence of general formula I R 1 -R 2 -R 3 -R 4 R -R R -R 8 wherein R' is selected from the group consisting of Asp, Glu, Asn, Acpc(1- aminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH2), Gly, Asp(NH 2 and Suc; R 2 is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, io D-Arg and D-Lys; R 3 is selected from the group consisting of Val, Ala, Leu, norLeu, lie, Gly, Pro. Aib, Acpc, and Tyr; R 4 is selected from the group consisting of Tyr, Tyr(PO 3 2 Thr, Ser, homoSer, Ala, and azaTyr; R 5 is selected from the group consisting of le, Ala, Leu, norLeu, Val and Gly; R" is His, Arg or 6-NH 2 -Phe; R 7 is Pro or Ala; and R8 is selected from the group consisting of Phe, Phe(Br), lie and Tyr; wherein the active agent does not include R 4 as a terminal Tyr group; 20 and wherein the compound is not SEQ ID NO: 1 for the manufacture of a medicament to promote neuronal cell proliferation or differentiation, which agent is substantially as herein described with reference to Example I or2.

23. Use of at least one active agent comprising a sequence consisting of the general formula: R 1 -ARG-VAL-TYR-R2-HIS-PRO-R3 wherein RI is selected from the group consisting of H or Asp; R2 is selected from the group consisting of lIe, Val, Leu, norLeu and Ala; R3 is either Phe or H; and wherein the compound is not SEQ ID NO:1 for the manufacture of a medicament to promote neuronal cell proliferation or differentiation.

24. The use of claim 23 wherein the active agent is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:26, and SEQ ID NO:34. I R.\L.I\'VV]02429peci.doc:nic 4 e, The use of claim 23 or 24 wherein the concentration of active agent is between about 0.1 ng/kg and about 10.0mg/kg.

26. The use of claim 18 wherein the active agent comprises at least four contiguous amino acids of general formula I.

27. The use of claim 18 wherein the active agent comprises at least five contiguous amino acids of general formula I.

28. The use of claim 18 wherein the active agent comprises at least six contiguous amino acids of general formula I.

29. The use of claim 18 wherein the active agent comprises at least seven I0 contiguous amino acids of general formula I. The use of claim 18 wherein the active agent consists of at least three contiguous amino acids of general formula I.

31. The use of claim 18 wherein the active agent consists of at least four contiguous amino acids of general formula 1. i 32. The use of claim 18 wherein the active agent consists of at least five contiguous amino acids of general formula I.

33. The use of claim 18 wherein the active agent consists of at least six contiguous amino acids of general formula I.

34. The use of claim 18 wherein the active agent consists of at least seven 20 contiguous amino acids of general formula I.

35. Use of at least one active agent comprising a sequence consisting of the general formula: R -ARG-VAL-TYR-R2-HIS-PRO-R3 wherein Rl is selected from the group consisting of H or Asp; 25 R2 is selected from the group consisting of Ile, Val, Leu, norLeu and Ala; R3 is either Phe or H; and wherein the compound is not SEQ ID NO: I, which agent is substantially as herein described with reference to Example 1 or 2.

36. At least one active agent comprising a sequence of at least three contiguous amino acids of groups R'-R 8 in the sequence of general formula I R'- R 2 R3 R 4 -R 5 -R-R R wherein R' is selected from the group consisting of Asp, Glu, Asn, Acpc(l- 1& aiminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 nd Suc; [R \I.1 VV|\02429~peci.docnic -4 31 R 2 is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R 3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, and Tyr; R 4 is selected from the group consisting of Tyr, Tyr(PO3) 2 Thr, Ser, homoSer, Ala, and azaTyr; R 5 is selected from the group consisting of le, Ala, Leu, norLeu, Val and Gly; R 6 is His, Arg or 6-NH 2 -Phe; R 7 is Pro or Ala; and i R is selected from the group consisting of Phe, Phe(Br), lie and Tyr; wherein the active agent does not include R 4 as a terminal Tyr group; and wherein the compound is not SEQ ID NO: 1, when used to promote neuronal cell proliferation or differentiation.

37. The agent of claim 36 wherein the active agent is selected from the group 4 i consisting of angiotensinogen, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID 20 NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36; and SEQ ID NO:37.

38. The agent of claim 36 or 37 wherein the active agent is SEQ ID NO:4, or SEQ ID NO:18.

39. The agent of any one of claims 36 to 38 wherein the concentration of active 2 agent is between about 0. Ing/kg and about 10.0mg/kg. At least one active agent comprising a sequence of at least three contiguous amiino acids of groups R'-R 8 in the sequence of general formula I R'-R 2 -R 3 -R 4 -R -R 6 -R 7 -R wherein R' is selected from the group consisting of Asp, Glu, Asn, Acpc(1- o0 aminocyclopentane carboxylic acid), Ala, Me 2 Gly, Pro, Bet, Glu(NH 2 Gly, Asp(NH 2 and Sue; R 2 is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R 3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, I R \L-lIVV 02429spccl.doc nic 9b i t C a es.. a S.. a e *r S a V a S 32 R 4 is selected from the group consisting of Tyr, Tyr(PO 3 2 Thr, Ser, homoSer, Ala, and azaTyr; R 5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly; R 6 is His, Arg or 6-NH 2 -Phe; R 7 is Pro or Ala; and R is selected from the group consisting of Phe, Phe(Br), Ile and Tyr; wherein the active agent does not include R 4 as a terminal Tyr group; and wherein the compound is not SEQ ID NO: 1, when used to promote neuronal cell proliferation or differentiation, which agent is substantially as herein in described with reference to Example 1 or 2.

41. At least one active agent comprising a sequence consisting of the general formula: R1-ARG-VAL-TYR-R2-HIS-PRO-R3 wherein R1 is selected from the group consisting of H or Asp; 5 R2 is selected from the group consisting of Ile, Val, Leu, norLeu and Ala; R3 is either Phe or H; and wherein the compound is not SEQ ID NO:1, when used to promote neuronal cell prliferation or differentiation.

42. The agent of claim 41 wherein the active agent is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:26, and SEQ ID NO:34.

43. The agent of claim 41 or 42 wherein the concentration of active agent is between about 0.1ng/kg and about 10.0mg/kg.

44. The agent of claim 36 wherein the active agent comprises at least four 25 contiguous amino acids of general formula I. The agent of claim 36 wherein the active agent comprises at least five contiguous amino acids of general formula I.

46. The agent of claim 36 wherein the active agent comprises at least six contiguous amino acids of general formula I.

47. The agent of claim 36 wherein the active agent comprises at least seven contiguous amino acids of general formula I.

48. The agent of claim 36 wherein the active agent consists of at least three contiguous amino acids of general formula I.

49. The agent of claim 36 wherein the active agent consists of at least four ntiguous amino acids of general formula I. IR \LI-llVV]l)2429spjcc doc:njc 1 33

50. The agent of claim 36 wherein the active agent consists of at least five o. contiguous amino acids of general formula I.

51. The agent of claim 36 wherein the active agent consists of at least six contiguous amino acids of general formula I.

52. The agent of claim 36 wherein the active agent consists of at least seven contiguous amino acids of general formula I.

53. At least one active agent comprising a sequence consisting of the general formula: R 1 -ARG-VAL-TYR-R2-HIS-PRO-R3 wherein R1 is selected from the group consisting of H or Asp; R2 is selected from the group consisting of Ile, Val, Leu, norLeu and Ala; R3 is either Phe or H; and wherein the compound is not SEQ ID NO:1, when used to promote neuronal cell proliferation or differentiation, which 15 agent is substantially as herein described with reference to Example 1 or 2.

54. The method of any one of claims 1-17, wherein the neuronal cell is a neuronal stem cell or progenitor cell.

55. The use of any one of claims 18-35, wherein the neuronal cell is a neuronal stem cell or progenitor cell.

56. The agent of any one of claims 36-53, wherein the neuronal cell is a neuronal stem cell or progenitor cell. S. 57. The method of any one of claims 1-17 and 54, wherein the method is used to treat a neurological disorder.

58. The method of claim 57, wherein the neurological disorder is selected from 25 the group consisting of Parkinson's disease, Alzeimer's disease, and amyotrophic lateral sclerosis. 0

59. The use of any one of claims 18-35 and 55, wherein the use is for treating a neurological disorder. The use of claim 59, wherein the neurological disorder is selected from the group consisting of Parkinson's disease, Alzeimer's disease, and amyotrophic lateral sclerosis.

61. The agent of any one of claims 36-53 and 56, wherein the agent is used to Streat a neurological disorder. treat a neurological disorder. [R:\LIBVV]03302.doc:aak 34

62. The agent of claim 61, wherein the neurological disorder is selected from the group consisting of Parkinson's disease, Alzeimer's disease, and amyotrophic lateral sclerosis.

63. At least one active agent as defined in any one of claims 36 to 53 together with a pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. Dated 6 May, 2002 University of Southern California Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *i